A Phase IIIb, Randomized, Active Controlled Open Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 Mg Daily In The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Who Have Had Progressive Disease While On 400 Mg Da

The main study is designed to demonstrate that sunitinib at a starting daily dose of 37.5 mg orally (with a continuous daily regimen) can significantly improve PFS compared with imatinib at a dose of 800 mg in patients whose disease has progressed during treatment with imatinib at a dose of 400 mg.